Inventor

UMANA PABLO

CH100 patents

⚠️ This page may combine multiple inventors who share the name “UMANA PABLO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

UMANA PABLO

ROCHE GLYCART AG

Mutant interleukin-2 polypeptides

Combination IL-2 immunoconjugate therapy

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Interleukin-10 fusion proteins

Immunoconjugates

Anti-FAP antibodies and methods of use

Mutant interleukin-2 polypeptides

Immunoconjugates

Anti-FAP antibodies and methods of use

Immunoconjugates

Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5

Anti-CEA antibodies

ASGPR antibodies and uses thereof

Anti-FAP antibodies and methods of use

Combination IL-2 immunoconjugate therapy

Mutant interleukin-2 polypeptides

Antibodies specific for DR5 and methods of use

Bispecific T cell activating antigen binding molecules

Interleukin-2 fusion proteins and uses thereof

HOFFMANN LA ROCHE

Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer

Bispecific antibodies specific for OX40

Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules

Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

Bispecific T cell activating antigen binding molecules

Bispecific T cell activating antigen binding molecules

Bispecific T cell activating antigen binding molecules

Bispecific antigen binding molecules comprising anti-FAP clone 212

Bispecific antibodies specific for PD1 and TIM3

GLYCART BIOTECHNOLOGY AG

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

UMANA PABLO

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

AST OLIVER

Immunoconjugates

Mutant interleukin-2 polypeptides

BRINKMANN ULRICH

Multispecific antibodies comprising full length antibodies and single chain fab fragments

Trivalent, bispecific antibodies

ENGMAB AG

Method for the selection of antibodies against BCMA

Bispecific antibodies against CD3 and BCMA

HOFER THOMAS U

Anti-CEA antibodies

BRUENKER PETER

DR5—FAP bispecific death receptor agonistic antibodies

HOFFMANN—LA ROCHE INC

Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety

ENGMAB SARL

Monoclonal antibodies against BCMA